Core Viewpoint - UTime Limited will implement a reverse share split of its Class A ordinary shares at a ratio of 1-for-10, effective on or around March 31, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][2][4]. Group 1: Reverse Share Split Details - The reverse share split will adjust the par value of the Ordinary Shares from $0.0001 to $0.001 per share and will continue trading under the symbol "WTO" on Nasdaq [2]. - The number of issued and outstanding shares will decrease from approximately 36 million to approximately 3.6 million [4]. - No fractional shares will be issued; fractional interests will be rounded up to the nearest whole number [3]. Group 2: Shareholder Information - VStock Transfer, LLC is designated as the exchange agent and will provide instructions to shareholders regarding the exchange of pre-reverse share split share certificates [5][6]. - Shareholders holding shares in book-entry form or brokerage accounts do not need to take any action for the reverse share split [5]. Group 3: Company Overview - UTime Ltd., established in 2008, focuses on providing cost-effective mobile devices globally, particularly aiding low-income individuals in both established and emerging markets [7]. - The company has expanded its product line to include smart electric vehicle chargers in response to global energy conservation demands [7].

Core Viewpoint - UTime Limited has received a notification from Nasdaq regarding non-compliance with minimum bid price requirements, as its share price has been below $1.00 for 30 consecutive business days [1][2]. Group 1: Company Compliance Status - The notification does not have an immediate effect on UTime's listing on Nasdaq [2]. - UTime has until April 8, 2025, to regain compliance with the minimum bid price requirement [2]. - If UTime's share price reaches at least $1 for 10 consecutive business days during the 180-day period, Nasdaq will confirm compliance [2]. Group 2: Potential Remedies - If UTime does not regain compliance within the initial 180-day period, it may be eligible for an additional 180 days, provided it meets other listing requirements [2]. - The company may consider a reverse stock split as a potential remedy to address the bid price deficiency [2]. Group 3: Company Overview - UTime Ltd. was established in 2008 and focuses on providing cost-effective mobile devices globally, particularly to low-income individuals in both established and emerging markets [3]. - The company has expanded its product line to include smart electric vehicle chargers in response to global energy conservation demands [3].

NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- UTime Limited (“UTime” or the “Company”) (Nasdaq: WTO), a mobile device manufacturing company committed to providing cost effective products and solutions to consumers globally and helping low-income individuals from established and emerging markets today announced that it has entered into a securities purchase agreement with certain accredited investor to sell $5 million of its ordinary shares in a registered direct offering. Under the terms of the securities pu ...

Company Overview - UTime Limited is a mobile device manufacturing company focused on providing cost-effective products and solutions to consumers globally, particularly targeting low-income individuals in both established and emerging markets [5] - The company has expanded its product line to include smart electric vehicle chargers in response to global energy conservation and carbon reduction demands since July 2023 [5] Reverse Share Split Announcement - UTime announced a reverse share split of its outstanding ordinary shares at a ratio of 1-for-25, effective on or around September 11, 2024 [1][2] - The reverse share split aims to help the company regain compliance with Nasdaq's minimum bid price requirement of $1.00 per ordinary share for continued listing [2] - Following the reverse share split, the number of issued and outstanding shares will decrease from approximately 450 million to about 18 million [3] Shareholder Information - No fractional shares will be issued; all fractional interests will be rounded up to the nearest whole number of ordinary shares [3] - VStock Transfer, LLC is designated as the exchange agent and paying agent for the reverse share split, and shareholders in book-entry form or brokerage accounts need not take any action [4]

SHENZHEN, China, Aug. 29, 2024 /PRNewswire/ -- Dear Investors, Analysts and Media:Recently, UTime Ltd ("UTime") has experienced a period of unusual share price volatility in the capital markets. As a responsible company, we understand the concerns of market participants about such situations and believe that it is necessary to provide the public with transparent and formalized information in this regard.First of all, the Board of Directors and management of the Company are highly concerned about the recent ...

Core Insights - UTime Limited has initiated comprehensive financial and legal due diligence on Bowen Therapeutics Inc, aiming to acquire the company to enhance its position in the innovative medical products sector [1][2][3] Company Overview - UTime Limited, established in 2008, focuses on providing cost-effective mobile devices globally and has recently shifted its commitment towards health and wellness through innovative medical wearable technologies since 2024 [5] Acquisition Strategy - The acquisition of Bowen Therapeutics is a strategic move for UTime, leveraging Bowen's strong reputation and unique R&D capabilities, particularly in the development of a monkeypox vaccine, to facilitate technological innovation and market expansion [2][3] Due Diligence Process - The due diligence process will encompass a thorough examination of Bowen Therapeutics's financial statements, assets, liabilities, cash flow, tax records, accounting systems, corporate governance, contracts, intellectual property rights, and any pending litigation [3][4] - This process is essential for UTime to assess potential risks and opportunities, ensuring informed decision-making aligned with the company's long-term growth strategy [4]

Core Insights - UTime Limited has announced a collaboration on Circul VS, a continuous blood pressure measurement technology system aimed at improving cardiovascular and cerebrovascular health management [1][2] - The Circul VS system includes BPwatch, Ring, and Smart Cradle, designed to monitor rapid blood pressure fluctuations, which are often overlooked by competitors [1][2] - The technology utilizes advanced ultrasound sensing and intelligent algorithms to provide real-time blood pressure waveform data with high accuracy, comparable to invasive methods [2][3] Company Overview - UTime Limited, established in 2008, focuses on providing cost-effective mobile devices and has recently shifted towards innovative medical wearable technologies for health and wellness [4] - The company aims to enhance global health management through strategic partnerships and cutting-edge research, targeting both established and emerging markets [4] Product Development - Circul VS has been developed for various clinical applications, including hypertension screening, long-term management of diagnosed patients, and acute monitoring in hospitals [3] - The system has undergone clinical trials in multiple hospitals, receiving positive feedback for its performance in non-invasive monitoring [2][3] - UTime plans to continue refining Circul VS to improve its intelligence and accuracy for broader use in medical settings, particularly in ICUs [3]

Core Viewpoint - UTime Limited is actively participating in international medical fairs and conferences to showcase its innovations in medical devices and solutions, aiming to enhance its global presence and partnerships in the healthcare industry [1][2]. Group 1: Upcoming Events - UTime will exhibit at MEDICA in Düsseldorf, Germany, focusing on medical monitoring devices and smart diagnostic tools, highlighting its innovations across the medical technology value chain [1]. - The company plans to attend several conferences in the United States, including the Cardiology Society Conference, Sleep Conference, and Hypertension Conference, providing a platform to present technological advancements and gain insights from industry experts [2]. Group 2: Commitment to Innovation - UTime's participation in these events reflects its commitment to influencing the global medical landscape and enhancing human health through technological innovation [2]. - The company aims to explore collaborative projects with international healthcare organizations and research institutes, particularly in telemedicine and artificial intelligence applications in healthcare, to accelerate the rollout of its products [3]. Group 3: Company Overview - UTime is dedicated to transforming health and wellness through innovative medical wearable technologies, leveraging research and strategic partnerships to provide effective solutions for disease prevention and health management globally [4].

Core Insights - UTime Limited is advancing its strategy in AI-driven health solutions, focusing on smart medical wearable products [1][2] - The company is collaborating with Dr. Ehud Baron to enhance its blood pressure measurement offerings and expand into hemodynamic and health mapping products [1] - UTime plans to launch additional products for monitoring key health indicators, including heart rate and sleep [2] Company Overview - UTime Limited, established in 2008, aims to provide cost-effective mobile devices globally, particularly for low-income individuals [3] - Since 2024, the company has been dedicated to transforming health and wellness through innovative medical wearable technologies [3] - UTime seeks to leverage research and strategic partnerships to offer effective solutions for disease prevention and health management [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________. OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR ...